Discover the Possibilities of Early PSMA-PET Scans
PSMA-PET testing offers precision diagnostics to inform targeted treatment with PLUVICTO® at the earliest eligible opportunity for metastatic prostate cancer.1
About PSMA
What is PSMA?
PSMA is a key biomarker for detecting and targeting metastatic prostate cancer2,3
PSMA serves as an actionable biomarker, providing an accessible target for ligand binding for BOTH imaging and treatment.1,4
IMAGING
 | PSMA is a transmembrane protein that is expressed in prostate cancer. PSMA-PET testing allows for detection of cells expressing this biomarker.1,2,5 |
TREATMENT
 | A positive PSMA-PET (uptake greater than liver in at least one metastatic lesion) allows selection for PSMA-targeted treatment.2,5 |
PSMA-PET imaging demonstrates high sensitivity and specificity for detecting PSMA+ metastases compared to conventional imaging.6-9
PSMA is not appreciably released into circulation, enabling specific targeting of PSMA-expressing cells and lesions with radioligands4
Scan early for PSMA expression to help determine eligibility for PSMA targeted therapy10
PET, positron emission tomography; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive.
PLUVICTO and PSMA-PET Testing
How does PSMA-PET testing impact the choice of targeted RLT?
PSMA-PET testing identifies patients with PSMA+ mPC early to open the door to targeted RLT as early as mAPMN/S PC (also known as mHSPC)1
With PSMA-PET confirmation of PSMA expression, patients can access targeted therapy with PLUVICTO.1
PLUVICTO is proven in three large phase 3 clinical trials,* and ~30k patients treated since FDA approval11-14,†
PLUVICTO delivers DNA-breaking radiation directly to PSMA+ cells, regardless of where they have metastasized (bone, nodal, or visceral)1
Refer patients with confirmed PSMA+ mPC to a specialized treatment center: PLUVICTO + ARPI for mHSPC, or PLUVICTO after 1 prior ARPI in mAPMR PC (also known as mCRPC)1
†Based on data from March 2026.14
ARPI, androgen receptor pathway inhibitor; mAPMN/S PC, metastatic androgen pathway modulation-naive or -sensitive prostate cancer; mAPMR PC, metastatic androgen pathway modulation-resistant prostate cancer; mCRPC, metastatic castration-resistant prostate cancer; mHSPC, metastatic hormone-sensitive prostate cancer; mPC, metastatic prostate cancer; RLT, radioligand therapy.
Practice Guidelines
NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) RECOMMENDED
 | Because of increased sensitivity and specificity, PSMA-PET scans are recommended by the National Comprehensive Cancer Network® (NCCN®) as an alternative to standard imaging throughout the prostate cancer journey3 |
At initial staging
For detection of biochemically recurrent disease3
To evaluate progression3,*
To establish eligibility for lutetium Lu 177 vipivotide tetraxetan (PLUVICTO)3
Progression in mCRPC after 1 ARPI
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
In the PLUVICTO trials, PSMA-PET determined PSMA expression for eligibility. Radiographic progression was assessed by conventional imaging (CT/MRI and bone scan), not PSMA-PET.
In mPC,
UTILIZE EARLY PSMA-PET TESTING TO MANAGE TREATMENT AND ASSESS PLUVICTO AT THE EARLIEST ELIGIBLE OPPORTUNITY